Radioactive Iodine

Introduction

Definition and Overview

Radioactive iodine refers to isotopes of iodine that possess unstable nuclei and emit ionising radiation. These isotopes are employed in both diagnostic imaging and therapeutic interventions, particularly within the field of endocrinology. The principal therapeutic isotope, iodine‑131 (I‑131), delivers beta and gamma radiation, enabling the selective ablation of thyroid tissue. Diagnostic isotopes, such as iodine‑123 (I‑123) and iodine‑125 (I‑125), emit low‑energy photons suitable for scintigraphic imaging. The unique ability of the thyroid gland to selectively concentrate iodine underpins the clinical utility of these agents.

Historical Background

In the early twentieth century, the discovery of radioactivity by Henri Becquerel and the subsequent elucidation of the iodine cycle by Arnon and Segrè laid the groundwork for therapeutic applications. The first clinical use of I‑131 for hyperthyroidism occurred in the 1940s, with subsequent refinement of dosage protocols and imaging techniques over the following decades. The advent of gamma cameras and single‑photon emission computed tomography (SPECT) further expanded diagnostic capabilities, while the development of positron emission tomography (PET) with fluorine‑18 enabled indirect imaging of iodine metabolism through surrogate tracers.

Importance in Pharmacology and Medicine

Radioactive iodine occupies a distinctive niche in pharmacology, blending nuclear physics with pharmacokinetics and clinical therapeutics. Its selective uptake by thyroid follicular cells allows for targeted delivery of cytotoxic energy, thereby minimizing systemic toxicity. In pharmacotherapy, the concept of iodine transport, organification, and radioactive decay forms a core component of the therapeutic index for thyroid disorders. The integration of radiotherapy with systemic agents exemplifies a multidisciplinary approach that is increasingly relevant in contemporary oncology and endocrine practice.

Learning Objectives

• Describe the physicochemical properties and production methods of commonly used radioactive iodine isotopes.
• Explain the mechanisms of iodine uptake, organification, and retention within the thyroid gland.
• Analyse pharmacokinetic and dosimetric principles governing therapeutic and diagnostic applications.
• Identify patient selection criteria, contraindications, and safety measures associated with radioactive iodine therapies.
• Apply clinical reasoning to case scenarios involving the use of radioactive iodine in endocrine disorders.

Fundamental Principles

Core Concepts and Definitions

Radioactive iodine isotopes are defined by their proton number (Z = 53) and varying neutron counts, resulting in distinct half‑lives and radiation emissions. Key isotopes include:

• I‑123 (half‑life 13.2 h, γ emission 159 keV)
• I‑125 (half‑life 59.4 days, low‑energy γ emission 35 keV)
• I‑131 (half‑life 8.04 days, β‑emission 606 keV, γ emission 364 keV)
• I‑129 (half‑life 15.7 million years, β‑emission 16 keV)

The term “effective dose” refers to the stochastic risk associated with whole‑body exposure, whereas “absorbed dose” quantifies the energy deposited per unit mass within a specific organ. The “therapeutic index” is the ratio of the target organ dose to the dose received by non‑target tissues.

Theoretical Foundations

The therapeutic effect of I‑131 is governed by the interplay of physical decay, biological uptake, and radiation transport. The radioactive decay follows first‑order kinetics, described by the equation:

A(t) = A₀ e^(–λt) where λ = ln 2/T½. The biological clearance from the thyroid follows a separate exponential decay with a biological half‑life (T_b), leading to an effective half‑life (T_eff) calculated by 1/T_eff = 1/T_½ + 1/T_b. The absorbed dose (D) to the thyroid is then approximated by D = ∫A(t) dt × E, where E is the mean energy per decay.

In diagnostic imaging, the photon flux (Φ) detected by a scintillation detector is proportional to the product of the administered activity and the fraction of photons escaping the patient, modified by attenuation coefficients and detector efficiency.

Key Terminology

• Organification – enzymatic incorporation of iodide into thyroglobulin.
• Thyroid‑stimulating hormone (TSH) – regulator of iodine uptake.
• Radioiodine uptake (RAIU) – percentage of administered iodine absorbed by the thyroid within a specified time.
• Effective dose (mSv) – risk assessment metric.
• Cumulative dose – total activity administered over a treatment course.

Detailed Explanation

Production and Quality Control

Commercial production of I‑131 typically involves cyclotron irradiation of enriched potassium iodide (KI) targets, generating I‑131 via the ^127I(n,α)^124Xe reaction. Subsequent radiochemical separation yields high‑purity I‑131 suitable for therapeutic use. Quality control parameters include radionuclidic purity, specific activity, chemical purity, and sterility. Regulatory agencies mandate stringent limits on contaminant isotopes such as I‑125 or I‑129, as well as on residual solvents and endotoxins.

Mechanisms of Thyroid Uptake

Thyroid follicular cells express the sodium‑iodide symporter (NIS), a transmembrane protein responsible for active transport of iodide from the bloodstream into the follicular lumen. The process is TSH‑dependent, with secretion patterns influenced by circadian rhythms and dietary iodine intake. Once inside the lumen, iodide undergoes oxidative organification mediated by thyroid peroxidase (TPO), culminating in the synthesis of thyroglobulin (Tg). I‑131, being chemically indistinguishable from stable iodine, follows the same transport and organification pathways, enabling selective deposition of radioactivity within the thyroid.

Pharmacokinetics and Dosimetry

After ingestion, radioactive iodine is absorbed in the gastrointestinal tract, enters the bloodstream, and is distributed to the thyroid and extrathyroidal tissues. The effective half‑life in the thyroid is a composite of physical decay and biological excretion, typically ranging from 3 to 7 days for I‑131 in hyperfunctioning tissue. Dosimetric calculations employ the MIRD (Medical Internal Radiation Dose) schema, incorporating residence times (τ) for each organ and S-values (dose per unit cumulated activity). For therapeutic planning, a target dose of 30–50 Gy is often desired for ablation of residual thyroid tissue, while minimizing exposure to salivary glands and bone marrow.

Factors Affecting Radioiodine Distribution

1. TSH Levels – Elevated TSH increases NIS expression, enhancing uptake.
2. Dietary Iodine – Iodine‑rich diets competitively inhibit uptake.
3. Medications – Amiodarone, lithium, and other agents can alter uptake kinetics.
4. Age and Renal Function – Reduced clearance in older adults prolongs systemic exposure.
5. Concurrent Radioisotopes – Co‑administration of diagnostic isotopes may affect biodistribution.

Radiation Physics and Biological Effects

Beta particles emitted by I‑131 possess a mean energy of 606 keV, with a maximum range of approximately 2 mm in tissue. This limited penetration confines cytotoxic energy to the thyroid gland. The accompanying gamma photons (364 keV) enable external detection for dosimetry and imaging. The biological impact of beta irradiation includes DNA strand breaks, apoptosis, and cell cycle arrest. Acute radiation syndrome is unlikely at therapeutic doses due to the localized nature of delivery, but chronic exposure may increase the risk of secondary malignancies in adjacent tissues.

Clinical Significance

Relevance to Drug Therapy

Radioactive iodine therapy constitutes a cornerstone of pharmacologic management for differentiated thyroid carcinoma, Graves’ disease, and toxic multinodular goiter. Its mechanism of action exemplifies targeted radiopharmaceutical therapy, achieving high therapeutic indices while sparing non‑target tissues. In oncology, the use of I‑131 in combination with tyrosine kinase inhibitors demonstrates the evolving paradigm of multimodal treatment regimens.

Practical Applications

• Therapeutic Ablation – Post‑thyroidectomy ablation of residual thyroid tissue and metastatic lesions.
• Diagnostic Imaging – Functional assessment of thyroid nodules, RAIU testing, and post‑treatment evaluation.
• Theranostics – Integration of diagnostic and therapeutic isotopes for personalized medicine.
• Research – Studies on radioiodine metabolism, gene expression, and novel delivery systems.

Clinical Examples

In differentiated thyroid carcinoma, 10–15 mCi of I‑131 is typically administered for ablation, with higher activities reserved for metastatic disease. For Graves’ disease, typical therapeutic doses range from 5 to 30 mCi, adjusted based on thyroid uptake and gland size. In toxic multinodular goiter, a single high‑dose administration (20–30 mCi) may achieve euthyroidism, although relapse rates can be significant.

Clinical Applications/Examples

Case Scenario 1 – Post‑Thyroidectomy Ablation

A 45‑year‑old woman undergoes total thyroidectomy for papillary thyroid carcinoma. Pre‑operative RAIU is 45 % at 24 h. Post‑operative planning involves administration of 15 mCi of I‑131. Dosimetry calculations yield an absorbed dose of 35 Gy to residual tissue, while estimated radiation exposure to bone marrow remains below 0.5 Gy. Post‑therapy whole‑body scans confirm adequate distribution, and follow‑up thyroglobulin levels decline to <1 ng/mL within 6 months.

Case Scenario 2 – Graves’ Disease Management

A 32‑year‑old man presents with thyrotoxicosis and a 3 cm goiter. RAIU at 24 h is 70 %. After an iodine‑deprivation diet for 4 weeks, 10 mCi of I‑131 is administered. The patient experiences transient nausea and mild xerostomia but returns to euthyroid status within 3 months. Serum thyroglobulin remains undetectable, suggesting complete ablation of hyperfunctioning tissue.

Case Scenario 3 – Metastatic Papillary Carcinoma

A 58‑year‑old woman with cervical lymph node metastases receives 30 mCi of I‑131. Imaging demonstrates uptake in cervical nodes and a solitary lung lesion. Subsequent SPECT/CT confirms focal activity. Following administration, the patient experiences mild bone marrow suppression (WBC decrease 20 %), managed with growth factors. The treatment yields partial remission, with a 12‑month progression‑free survival.

Problem‑Solving Approach

1. Assess baseline thyroid function and RAIU.
2. Determine target organ dose required for therapeutic effect.
3. Calculate cumulative activity, considering effective half‑life and patient’s metabolic rate.
4. Implement iodine‑deprivation and medication adjustments to optimise uptake.
5. Monitor for adverse effects and adjust dosage accordingly.

Summary/Key Points

• Radioactive iodine isotopes deliver targeted radiation to the thyroid via NIS‑mediated uptake and organification.
• I‑131 is the principal therapeutic isotope, with a half‑life of 8 days and beta emission suitable for tissue ablation.
• Dosimetry relies on the MIRD schema, integrating residence times and S-values to estimate absorbed dose.
• Patient preparation, including iodine‑deprivation and medication review, significantly influences therapeutic efficacy.
• Common adverse effects include transient nausea, xerostomia, and, rarely, bone marrow suppression; strict radiation safety protocols mitigate secondary malignancy risk.
• Future directions involve theranostic approaches, novel delivery vectors, and combination therapies to enhance specificity and reduce toxicity.

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
8. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.